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ABSTRACT
Introduction Most asthma attacks and subsequent 
deaths are potentially preventable. We aim to develop 
a prognostic tool for identifying patients at high risk of 
asthma attacks in primary care by leveraging advances in 
machine learning.
Methods and analysis Current prognostic tools use 
logistic regression to develop a risk scoring model 
for asthma attacks. We propose to build on this by 
systematically applying various well- known machine 
learning techniques to a large longitudinal deidentified 
primary care database, the Optimum Patient Care 
Research Database, and comparatively evaluate their 
performance with the existing logistic regression model 
and against each other. Machine learning algorithms vary 
in their predictive abilities based on the dataset and the 
approach to analysis employed. We will undertake feature 
selection, classification (both one- class and two- class 
classifiers) and performance evaluation. Patients who 
have had actively treated clinician- diagnosed asthma, 
aged 8–80 years and with 3 years of continuous data, 
from 2016 to 2018, will be selected. Risk factors will be 
obtained from the first year, while the next 2 years will 
form the outcome period, in which the primary endpoint 
will be the occurrence of an asthma attack.
Ethics and dissemination We have obtained approval 
from OPCRD’s Anonymous Data Ethics Protocols and 
Transparency (ADEPT) Committee. We will seek ethics 
approval from The University of Edinburgh’s Research 
Ethics Group (UREG). We aim to present our findings at 
scientific conferences and in peer- reviewed journals.
INTRODUCTION
Asthma is a common and heterogeneous 
disease that affects approximately 300 million 
people worldwide; in most parts of the world 
its prevalence is growing or remaining stable 
at best.1 Around 180 000 deaths are attributed 
to asthma per year, the majority of which are 
preventable. Asthma attacks (also termed 
asthma exacerbations) can affect people with 
asthma of any age, ethnicity and severity. 
In the UK, there are each year at least 6.3 
million primary care consultations, 93 000 
hospital inpatients episodes and 1400 deaths 
have been attributed to asthma, costing the 
UK public sector over £1.1 billion.2
Asthma is a variable condition. Most people 
with asthma thus have long periods where 
they are either asymptomatic or experience 
only relatively mild symptoms and then expe-
rience asthma attacks, which may prove life- 
threatening. Asthma self- management plans 
aim to support patients/carers in identifying 
when asthma control is deteriorating and 
then encouraging patients to modify treat-
ment accordingly to improve asthma control. 
This is at present largely a qualitative process 
as there is no widely used algorithm to help 
predict the risk of an asthma attack.
The limited existing body of evidence on 
this subject reveals that most investigators 
have employed univariate regression model-
ling to identify one or more risk factors for 
Strengths and limitations of this study
 ► Comparison of a variety of machine learning ap-
proaches with a logistic regression model to develop 
a prognostic tool for predicting asthma attacks will 
be done.
 ► First study to apply novelty detection (a one- class 
classifier) for predicting asthma attacks using pri-
mary care data.
 ► Standardised performance evaluation measures 
will be used when comparing machine learning 
algorithms.
 ► A very large national primary care dataset will be 
utilised, with a population of people with asthma, 
which will increase the likelihood that results will be 
generalisable.
 ► Some potentially important risk factors, such as in-
haler technique and allergen exposure are absent 
from this database, and we will not be validating this 
work against another dataset.
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asthma attacks. Such studies assess the independent 
contribution of each of several factors, and do not deter-
mine the predictive performance of an optimal combina-
tion of factors in individual patients. In contrast, a limited 
number of studies have attempted to combine various 
risk factors in order to develop a risk scoring algorithm. A 
comprehensive systematic review by Loymans et al3 aimed 
to identify and critically appraise predictive models which 
assess future risk of asthma attacks. They were able to iden-
tify 24 models from 12 studies, using a search up to April 
2017, in which multiple factors (referred to as predictors 
henceforth) were accounted for and predictive perfor-
mances were evaluated. They concluded that a generalis-
able model for predicting severe attacks is feasible, as the 
predictive properties of most models were comparable 
in two distinct validation populations, and that there is 
scope for improved performances. A major limitation 
of the studies reviewed was the small population size. 
Except one study,4 all studies reviewed had a population 
size of less than 8000, and consequently a low number 
of asthma attacks. Variations in model performance was 
attributed to design methodologies, reporting and differ-
ences in asthma outcomes. The definition of an asthma 
attack varied between studies, with some using just one, 
or combination, of the following: prescription of oral 
corticosteroids, attending the accident and emergency 
department and/or hospital admission for asthma. The 
definition of uncontrolled asthma also varied, with some 
studies using subjective measures, such as data in patient 
diaries. We have identified Blakey et al5 as our bench-
mark study (excluded from Loymans et al for reporting 
relative risk rather than absolute risk), as it successfully 
addresses many of our aforementioned limitations asso-
ciated with developing a risk score. This study effectively 
identified patients at risk of recurrent attacks using the 
Optimum Patient Care Research Database (OPCRD) 
database, which contained longitudinal medical records 
of 118 819 patients with asthma, and was broadly repre-
sentative of the general asthma population in the UK. 
Various predictors (or features) for attacks were identi-
fied and evaluated using logistic regression—building on 
the work by Price et al6—and entered into a multivariate 
logistic regression analysis with feature selection using 
backward elimination, based on the importance of indi-
vidual features. The resultant risk score for recurrent 
attacks over a 2- year outcome period, was used to develop 
an online asthma risk prediction tool for research and 
clinical purposes.7 There is however a need to build on 
this study, as it only utilised logistic regression, which has 
been shown to be a poor classifier in cases of class imbal-
ance (ie, disproportionate ratio of event vs no event data) 
which is the case for asthma attacks in a population.8 In 
addition, logistic regression is a two- class classifier (ie, it 
requires reasonable number of samples of both classes to 
adequately model the data). Two class- classifiers are the 
most common approach and all previous studies have 
attempted to model asthma attack using a two- class classi-
fier. However, in situations where an event is rare (such as 
asthma attacks in this study), novelty detection (one- class 
classifier) can perform better as it only requires exam-
ples of one class that is common (in our case, it would 
be the periods over which an individual had no asthma 
attacks) to build a model. While novelty detection has 
been applied in several healthcare applications such as 
detection of masses in mammograms,9 condition moni-
toring of patients in intensive care unit10 and identifica-
tion of children with infection,11 we are not aware of any 
previous study that has applied novelty detection for the 
prediction of asthma attacks.
Since machine learning algorithms vary in their predic-
tive abilities dependent on the underlying application 
and distribution of data, a range of methodologies need 
to be employed and compared in an attempt to improve 
performance.
Research aims
We propose leveraging advancements in machine 
learning by systematically evaluating different model-
ling approaches, to develop a prognostic tool for asthma 
attacks that is an improvement over the current state- of- 
the- art logistic regression- based approach.6
Specifically, we aim to:
1. Identify significant risk factors associated with asthma 
attacks in children, adolescents and adults (aged 8–80 
years), and appropriately select these for inclusion in 
our analysis.
2. Systematically apply several machine learning algo-
rithms (both one- class classifier and two- class classifi-
ers) to predict the risk of asthma attacks, over 3- month, 
6- month, 12- month and 24- month outcome periods.
3. Comparatively evaluate performances of these predic-
tive models with each other and against the bench-
mark logistic regression model, to identify which is the 
most accurate.
METHODS
Figure 1 provides an overview of our methodology. Once 
the data have been extracted, it will be divided into training 
and testing sets, using k- fold cross- validation. The training 
data will then be used to develop a risk prediction model. 
The key steps for developing this model are feature selec-
tion and training a classifier model. The trained classi-
fier will then be tested on the remaining data (the testing 
set) for validation. It is important to point out that some 
methods combine feature selection and classifier within 
a single step known as embedded methods (hence the 
dashed line combining feature selection with classifier).
Patient and public involvement
We aim to work closely with the members of the Patient 
and Public Involvement group of the Asthma UK Centre 
for Applied Research, University of Edinburgh during 
this research. We will seek input from the PPI group to 
comment on the findings of the study and help us in 
disseminating the key findings to the public via social 
media, website and various public engagement activities.
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Study design and population
We will conduct a retrospective cohort study, using 
OPCRD, a longitudinal deidentified primary care data-
base of over 6.3 million patients from over 700 general 
practices in the UK. The medical record data for each 
patient will include demographic information, disease 
diagnoses in the form of Read codes, drug prescriptions, 
medical test results and hospitalisation information. 
The three most recent years of continuous data for each 
patient will be analysed, from which 1 year will be for 
baseline characterisation, and the other two will form the 
outcome data.
The study population will consist of patients with actively 
treated asthma (‘asthma diagnostic’ Read codes prior to 
study commencing, and a current asthma prescription), 
aged 8–80 years and with three or more years of contin-
uous data. This study will focus on adults and young 
people aged 8 years and over. Missing data on age and/
or sex, will result in patient exclusion; this along with any 
other patient exclusions will be documented. We will not 
attempt to exclude patients with comorbidities. We have, 
however, included comorbidities as one of the candidate 
predictors (see table 1) that will allow us to adjust for any 
potential confounders arising from comorbidities.
Active asthma will be defined by a prescription with  ≥
 2 asthma drugs during year 1 of the study, to include any 
of short- acting beta agonists, long- acting beta antagonists 
(LABA), inhaled corticosteroids (ICS), fixed- dose ICS/
LABA combination, leukotriene receptor antagonists 
and/or theophylline, along with the absence of a Read 
code for resolved asthma at any point during the 3- year 
study period. For all characteristics derived from Read 
codes, full code lists will be provided as online supple-
mentary materials.
Potential risk factors
The candidate predictors for asthma attacks, to be assessed 
for inclusion in the models will be from the baseline study 
by Blakey et al,5 which selected measures that are routinely 
collected in primary care, as shown in table 1. Variables 
with missing data, other than age and/or sex (exclusion 
criteria), will be dealt with using multiple imputation.12
Outcome ascertainment
The primary outcome for each model will be the occur-
rence of an asthma attack, as defined by the European 
Respiratory Society/American Thoracic Society,13 namely 
prescription of oral corticosteroids following an acute 
presentation of asthma, an accident and emergency atten-
dance for asthma or an asthma- related hospitalisation.
Analysis plan
Feature selection
An important stage, prior to the application of many 
well- known classifiers, is the selection of appropriate risk 
factors, termed ‘feature selection’ in machine learning. 
This works to avoid the problem of overfitting, thereby 
increasing generalisability, and improving model accu-
racy. We will first generate a correlation heat map to 
visually assess which features are most correlated with an 
asthma attack.14 Univariate analysis, such as correlation 
heatmaps, do not take the interaction of features into 
consideration. We will, therefore, subsequently use the 
ReliefF algorithm that will allow us to rank features based 
on their predictive power.15
Classification
Supervised classification algorithms will be used to obtain 
a classifier which can differentiate between stable asthma 
and a patient profile that is at risk of an attack. Figure 2 
provides an overview of the classification algorithms that 
we will explore. Broadly, there are two types of supervised 
classification algorithms that we will explore: one- class 
classifier and a two- class classifier.
The first step within a one- class classifier is to learn a 
probabilistic model of normality in n dimensions (where 
n is the number of features). There are two main types of 
models for learning the unconditional probability density 
function characterising normality: Parzen Windows and 
Figure 1 Flowchart of proposed steps in the methodology. 
OPCRD,Optimum Patient Care Research Database.
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Table 1 Candidate predictors to be assessed for inclusion in models (adapted from Blakey et al5)
Variable Description
Sex Male or female
Age In years at the start of the 3- year study period
BMI Last recorded, in kg/m2; categorised as underweight (<18.5), normal (18.5–24.9), overweight 
(25-
29.9) or obese (≥30)
Ethnicity Ethnicity information if available (white, black, Asian, South Asian Caribbean etc)
Smoking status Last recorded, categorised as never smoker, current smoker or ex- smoker
Charlson comorbidity index Score in the baseline year, categorised as 0, 1–4, 5–9, ≥10
Comorbidities* Recorded ever or active: eczema, allergic and non- allergic rhinitis, nasal polyps, 
anaphylaxis diagnosis, anxiety/depression diagnosis, diabetes (type 1 or 2), GERD, 
cardiovascular disease, ischaemic heart disease, heart failure, psoriasis
Comedications In baseline year, prescription (yes/no) for paracetamol, NSAIDs, beta- blockers, statins
% predicted PEF Recorded ever, expressed as percentage of predicted normal, categorised as 
unknown,<60%,
61%–79% and ≥80%
Blood eosinophil count Last recorded, in 109 cell/L, categorised as ≤0.4 or >0.4
BTS step†   
  Step 1 Inhaled SABA as needed
  Step 2 ICS or LTRA
  Step 3 Add LABA to ICS or use high- dose ICS (≥400 mg/day FP equivalent)
  Step 4 Add LTRA/Theo to (ICS+LABA) or add LABA/LTRA/Theo to high- dose ICS
  Step 5 Add OCS
Average daily dose of SABA/ICS Cumulative dose of SABA/ICS prescribed in baseline year, expressed in mg/day albuterol or 
FP equivalent and divided by 365.25
Prescribed daily ICS dose Dose of ICS prescribed at last prescription of baseline year in mg/day, FP equivalents
ICS medication possession ratio ICS refill rate during the baseline year: sum of number of days per pack (number of 
actuations per pack/number of actuations per day)/365.25
ICS device type In baseline year: categorised as no ICS, MDI, BAI or DPI
Spacer use with ICS pMDI Recorded in baseline year (yes/no)
Oral corticosteroid use Any maintenance prescription for corticosteroids in baseline year (yes/no)
Prior asthma education Recorded ever (yes/no)
Primary care consults Number of primary care consultations, categorised as 0, 1–5, 6–12, ≥13
Primary care consults for asthma Number of primary care consultations with an asthma- related Read code
Antibiotics with lower respiratory 
consult
Number of consultations that resulted in antibiotic prescription (included to capture asthma 
events that may have been misclassified as LRTI)
Acute respiratory events Number of events in the baseline year, defined as asthma- related hospitalisation or ED 
attendance or an acute course of OCS or antibiotics prescription with lower respiratory 
consultation
Acute OCS courses Number of acute courses of OCS in baseline year, categorised as 0, 1, ≥2
Acute OCS courses with lower 
respiratory consult
Number of OCS courses with Read code for lower respiratory consultation in baseline year, 
categorised as 0, 1, ≥2
Antibiotics courses Number of antibiotics prescriptions with Read code for lower respiratory consultation in 
baseline year, categorised as 0, 1, ≥2
Hospital attendance/admission Number of asthma- related‡ ED, inpatient and outpatient attendance/admission in baseline 
year (as recorded in primary care data)
Asthma attacks Number of asthma- related‡ hospital ED attendance, inpatient admission or acute OCS 
course
Eosinophil count Blood eosinophil count (cells/L) categorised into high and not high (threshold of 0.35×109 
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Gaussian Mixture Modelling.16 Following the learning 
or training phase, the data fusion model of normality is 
used to evaluate the probability that the features acquired 
from a subject in a test set (ie, a subject not included in 
the training set) can be considered to be normal. Novelty 
detection identifies those subjects with features outside 
the distribution of normality.
Two- class classifiers can broadly be categorised into 
discriminative models (these methods learn a decision 
boundary using the training data) and generative models 
(these models learn the underlying probability distribu-
tion of the data and then use Bayes formula for classi-
fication). For generative models, we will use the naive 
Bayes algorithm. For discriminative models, we will 
first use logistic regression—the most commonly used 
method in the field of medicine, hence will be used as 
our benchmark approach (as was done in Blakey et al5). 
However, logistic regression can only learn a linear deci-
sion boundary in the feature space and we will subse-
quently apply additional discriminative classification 
algorithms in our pursuit of developing a prognostic tool. 
This comparative approach is used commonly in the field 
of machine learning.17 The additional algorithms we will 
explore are ‘Support Vector Machines’ (SVMs) which 
seek to find an optimal hyperplane in n- dimensional 
space for separating two classes (the maximum- margin 
hyperplane). In SVM, the decision points are defined by 
only the training points that are closest to the boundaries 
(the support vectors). By using a ‘kernel trick’, the SVM 
can be used to find a non- linear boundary. We will also 
explore the use of ‘Decision Trees’ which are widely used 
in healthcare due to their simplicity and ease of inter-
pretability. The aforementioned algorithms were selected 
based on evidence in the literature on their use in predic-
tive modelling.18 19Lastly, traditional feature selection 
techniques can be sensitive to random error, hence we 
also propose the use of Least Absolute Shrinkage and 
Selection Operator (LASSO).20 LASSO is a modification 
of logistic regression where the cost function includes an 
additional term (a regularisation term which is the sum 
of the absolute values of the unknown parameters to be 
found). Effectively, it is an embedded technique that 
combines classification learning and feature selection by 
systematically removing (or knocking out) features based 
on their predictive ability. This technique can thus help 
us rank features based on their importance (ie, predictive 
power) as well as enhance the prediction accuracy and 
interpretability of the classifier.
Performance evaluation
K- fold cross- validation will be used to estimate the predic-
tive accuracy of each machine learning model on unseen 
data. Each round of cross- validation involves the splitting 
of the dataset into subsets (the parameter K refers to the 
number of subsets), following which the algorithm is 
trained on one subset (termed the ‘training set’), and is 
Variable Description
*Comorbidity recorded ‘ever’ was defined as a diagnostic Read code during the baseline year or at any time before baseline. ‘Active’ refers 
to those for which a diagnosis was recorded within the baseline year and/or a previous diagnosis was accompanied by a prescription for the 
comorbidity within the baseline year. ‘Rhinitis’ included allergic and non- allergic rhinitis.
†Based on the British guideline on the management of asthma (October 2014) for adults and children.25
‡Any patient with a lower respiratory Read code (asthma or LRTI code).
BAI, Breath- actuated inhaler; BMI, body mass index; BTS, British Thoracic Society; DPI, dry powder inhaler; ED, emergency department; FP, 
fluticasone propionate; GERD, gastro- oesophageal reflux disease; ICS, inhaled corticosteroids; LABA, long- acting beta antagonists; LRTI, 
lower respiratory tract infection; LTRA, leukotriene receptor antagonist; MDI, metered- dose inhaler; NSAIDs, non- steroidal anti- inflammatory 
drugs; OCS, oral corticosteroids; PEF, peak expiratory flow; SABA, short- acting b2 agonist; Theo, theophylline.
Table 1 Continued
Figure 2 Overview of the various classification algorithms that will be used to predict asthma attack. The methods are broadly 
divided into one- class classifier and two- class classifier. Our baseline reference method is logistic regression (shown in green).
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then validated against another subset (termed the ‘vali-
dation set’ or ‘testing set’). In order to reduce variability, 
multiple rounds of cross- validation are performed, with 
different subsets from the same dataset, and the average 
cross- validation error is used as a performance indicator.
Model evaluation will be carried out quantitatively via 
receiver operator characteristic (ROC) analysis. ROC 
curves will be constructed to evaluate and compare the 
predictive models. A ROC curve plots sensitivity (ie, the 
proportion of positive cases that are correctly identified) 
and specificity (ie, the proportion of negative cases that 
are correctly identified) at a range of threshold settings. 
The area under the curve provides an aggregate measure 
of model performance across all classification thresholds 
and will be used to compare predictive models.
DISCUSSION
This is the first study that will leverage advances in 
machine learning to develop a prognostic tool for asthma 
attacks using a UK- wide dataset. It is also the first study 
that will apply a one- class classifier (novelty detection) to 
predict asthma attack using routinely collected primary 
care data. It will fill an important gap in the evidence base, 
as similar studies carried out to- date have utilised single 
models (primarily logistic regression and lacking compar-
ative algorithm analysis) and none have utilised novelty 
detection. A study protocol21 was recently published, for 
developing a machine learning- based prediction tool for 
asthma attacks, which will employ novel applications of 
established machine learning. However, the model will be 
derived and validated using data across Scotland, and the 
work will only focus on two- class classifiers. Our study will 
be based on a general population of people with asthma, 
with data obtained from a large UK- wide dataset. Our 
findings will therefore be applicable to patients under-
going treatment for asthma in the UK and can potentially 
inform clinical practice. A variety of machine learning 
algorithms have been selected for comparison, based on 
evidence from the literature on their uses, and the perfor-
mance evaluation measures to be used are also standard, 
well- accepted approaches.
One limitation of our study is the absence of some 
potentially important risk factors from the database 
(based on reports from previous studies22), including 
allergen exposure and inhaler technique, along with 
the lack of another independent dataset for validating 
models. Another limitation is not all asthma attacks will 
be captured in routinely collected structured electronic 
health records. There is the potential to use natural 
language processing- based approaches to interrogate the 
free text records and this may increase the accuracy with 
which such events are detected. Furthermore, we do not 
have access to pharmacy records for prescription data 
(which may help us better estimate patient adherence 
to medication prescription) and would therefore use 
prescription records to determine patient usage which 
may not always be the correct.
Following the development of our prognostic tool, 
independent validation will be required using another 
large dataset. Prospective trials will then be needed in 
order to evaluate the implementation of the model in 
clinical practice, along with its effects on asthma- related 
outcomes in the population.
ETHICS AND DISSEMINATION
All authors with data access have completed the Safe 
Users of Research data Environment training, provided 
by the Administrative Data Research Network. All anal-
ysis will be conducted in concordance with the National 
Services Scotland Electronic Data Research and Innova-
tion Service (eDRIS) user agreement.
Our study protocol has been reviewed and ethically 
approved by The Anonymous Data Ethics Protocols and 
Transparency (ADEPT) committee, thereby receiving 
ADEPT Approval and access to the OPCRD.
The findings from this study will be reported in line 
with recommendations from the TRIPOD (transparent 
reporting of a multivariable prediction model for indi-
vidual prognosis or diagnosis) and RECORD (reporting 
of studies conducted using observational routinely 
collected health data) checklists.23 Code scripts used 
for all components of the data cleaning, compiling 
and analysis will be made available in the open source 
GitHub website at https:// github. com/ syedahmar. We 
aim to present the findings at national and international 
conferences, and publish them in leading peer- reviewed 
journals.
Acknowledgements The authors would like to thank Dominic Ng and Moiz A Shah 
for their contributions to the proof reading of this manuscript. We thank OPC for 
access to the OPCRD dataset.
Contributors ZH, SAS and AS conceived and planned the analysis. SAS with ZH 
wrote the first draft, with contributions from all authors (ZH, SAS, MM and AS). All 
authors approved the final version and jointly take responsibility for the decision to 
submit this manuscript to be considered for publication.
Funding Asthma UK Centre for Applied Research; The University of Edinburgh’s 
Chancellor’s Fellowship Scheme; BREATHE - The Health Data Research Hub 
for Respiratory Health [MC_PC_19004] funded through the UK Research and 
Innovation Industrial Strategy Challenge Fund and delivered through Health Data 
Research UK.
Competing interests None declared.
Patient and public involvement Patients and/or the public were involved in the 
design, or conduct, or reporting or dissemination plans of this research. Refer to the 
Methods section for further details.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Syed Ahmar Shah http:// orcid. org/ 0000- 0001- 5672- 0443
Mome Mukherjee http:// orcid. org/ 0000- 0002- 3083- 436X
 o
n




pen: first published as 10.1136/bmjopen-2019-036099 on 23 July 2020. Downloaded from 
7Hussain Z, et al. BMJ Open 2020;10:e036099. doi:10.1136/bmjopen-2019-036099
Open access
REFERENCES
 1 Anandan C, Nurmatov U, van Schayck OCP, et al. Is the prevalence 
of asthma declining? systematic review of epidemiological studies. 
Allergy 2010;65:152–67.
 2 Mukherjee M, Stoddart A, Gupta RP, et al. The epidemiology, 
healthcare and societal burden and costs of asthma in the UK and 
its member nations: analyses of standalone and linked national 
databases. BMC Med 2016;14:113.
 3 Loymans RJB, Debray TPA, Honkoop PJ, et al. Exacerbations in 
adults with asthma: a systematic review and external validation of 
prediction models. J Allergy Clin Immunol Pract 2018;6:1942–52.
 4 Grana J, Preston S, McDermott PD, et al. The use of administrative 
data to risk- stratify asthmatic patients. Am J Med Qual 
1997;12:113–9.
 5 Blakey JD, Price DB, Pizzichini E, et al. Identifying risk of future 
asthma attacks using UK medical record data: a respiratory 
effectiveness group initiative. J Allergy Clin Immunol Pract 
2017;5:1015–24.
 6 Price D, Wilson AM, Chisholm A, et al. Predicting frequent asthma 
exacerbations using blood eosinophil count and other patient data 
routinely available in clinical practice. J Asthma Allergy 2016;9:1–12.
 7 REG asthma risk calculator V 0.0.43.
 8 King G, Zeng L, Langche Zeng GHE, et al. Logistic regression in rare 
events data. Polit. anal. 2001;9:137–63.
 9 Tarassenko L, Hayton P, Cerneaz N, et al. Novelty detection for 
the identification of masses in mammograms. IEE Conference 
Publication, 1995.
 10 Tarassenko L, Hann A, Young D. Integrated monitoring and analysis 
for early warning of patient deterioration. Br J Anaesth 2006;97:64–8.
 11 Shah SA. Vital sign monitoring and data fusion for paediatric triage 
2012.
 12 Royston P. Multiple imputation of missing values: update. Stata J 
2005.
 13 Reddel HK, Taylor DR, Bateman ED, et al. An official American 
thoracic Society/European respiratory Society statement: 
asthma control and exacerbations. Am J Respir Crit Care Med 
2009;180:59–99.
 14 Roque FS, Jensen PB, Schmock H, et al. Using electronic patient 
records to discover disease correlations and stratify patient cohorts. 
PLoS Comput Biol 2011;7:e1002141.
 15 Durgabai RPL, Y RB. Feature selection using ReliefF algorithm. 
IJARCCE 2014:8215–8.
 16 Duda RO, Hart PE, Stork DG. Pattern Classification (Google EBook). 
2012. John Wiley & Sons, 2012.
 17 Naydenova E, Tsanas A, Howie S, et al. The power of data mining in 
diagnosis of childhood pneumonia. J R Soc Interface 2016;13:66.
 18 Padalia N, Naidu A. A heart disease prediction model using 
SVM- Decision Trees- Logistic regression (SDL). Int J Comput Appl 
2013;68:11–15.
 19 Huang H- H, Xu T, Yang J. Comparing logistic regression, support 
vector machines, and permanental classification methods in 
predicting hypertension. BMC Proc 2014;8:S96.
 20 Muthukrishnan R, Rohini R. LASSO: a feature selection technique 
in predictive modeling for machine learning. 2016 IEEE Int Conf Adv 
Comput Appl 2016.
 21 Tibble H, Tsanas A, Horne E, et al. Predicting asthma attacks in 
primary care: protocol for developing a machine learning- based 
prediction model. BMJ Open 2019;9:e028375.
 22 Reddel HK. The impact of the global initiative for asthma (GINA): 
COMPASS, concepts, controversies and challenges. BRN 2019;5.
 23 Struthers C, Struthers C. A new online tool from the EQUATOR 
network to help find and use reporting guidelines. EON 
2018;11:10–13.
 24 Kerkhof M, Tran TN, van den Berge M, et al. Association between 
blood eosinophil count and risk of readmission for patients with 
asthma: historical cohort study. PLoS One 2018;13:e0201143.
 25 Guide QR. Asthma Guidelines BTS - Inhalers 2014:1–28.
 o
n




pen: first published as 10.1136/bmjopen-2019-036099 on 23 July 2020. Downloaded from 
